CMANY
ENTA icon

Capital Management Associates (New York)’s Enanta Pharmaceuticals ENTA Stock Holding History

Capital Management Associates (New York)’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-7,600
Closed -$233K – 150
2015
Q1 		$233K Buy
+7,600
New +$296K 0.31% 129

Other funds holding ENTA

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
MVM
McClain Value Management New Canaan, Connecticut $50.9M AUM 16.06% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Capital Management Associates (New York)'s ENTA Position: Q2 2015 in Review

Capital Management Associates (New York) sold out of Enanta Pharmaceuticals (ENTA) in Q2 2015, closing a stake of 7,600 shares — an estimated $233K sold.

Capital Management Associates (New York) first reported a position in ENTA in Q1 2015 and held it in 1 quarter. The position peaked at $233K in Q1 2015. 132 funds tracked by Wall St. Rank hold ENTA as of Q2 2015.

  • Capital Management Associates (New York) reported no remaining Enanta Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Capital Management Associates (New York) sold 7,600 Enanta Pharmaceuticals shares in Q2 2015, an estimated $233K.
  • Capital Management Associates (New York) first reported a position in Enanta Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Capital Management Associates (New York)'s Enanta Pharmaceuticals position peaked at $233K in Q1 2015.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2015.

Based on Capital Management Associates (New York)'s 13F filing for Q2 2015, filed 22 Jul 2015.